In January 2015, then-president Barack Obama proposed the "Precision Medicine" plan.Since the FDA released the draft guidelines，“Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product”， in July 2016, there has been tremendous recognition in the industry.The FDA also approved a number of CDx products, and a number of CDx diagnostic kits were listed.With the development of companion diagnosis, targeted therapy, biomarkers, liquid biopsies, and so on, the development of precision medicine and personalized medicine has been promoted.Precision medicine is based on individual medical treatment. Liquid biopsies obtain tumor information through non-invasive sampling methods, and assist cancer treatment, which is the diagnostic technology of accurate medical representative.Companion Diagnostic is the key to accurate "Precision Medicine".
In order to promote the communication between people engaged in precision medicine,molecular diagnostic,gene sequencing and tumor treatment, Asia Companion Diagnostics&Prcision Medicine Summit 2018 has invited diagnostic industry leaders from famous scientific research insititues, goverment,pharmaceutical companies in Asia. We will discuss the future of Companion Diagnostic and Precision Medicine in Asia about the following topics： Companion Diagnstic Policy，Market and Commercialization，Biomarkers, Sequencing Technology,Precision Medicine Policy，Tumor Therapy and Single Molecule Sequencing。Welcom to join us！
Date
2018/4/26-2018/4/27
（Thursday，Friday）
Location
Shanghai · China
Scale
300+
Jiankui He
Chairman
Direct Genomics
Reiko Yanagihara
Deputy Review Director
PDMA
Remi Dangla
CEO
Stilla Technologies
Minzhi Ye
R&D Director
BGI Genomics
Zengjun Dong
GM for China&APAC
Cell Signaling Technology
Ningjun Jiang
Chairman
Cstone Pharmaceuticals
Yizhe Zhang
Chairman
Shuwen Biotech
Danyi Wen
Founder&President
LIDE Biotech
Han Liang
Co-founder&CSO
Precision Scientific
Abraham Ho
VP&CMO
LAM Group
Mingde Xia
Director
APAC Innovative Center J&J
Mike Zhu
EVP
Amoydx
Johny Zhang
Founder
Singlera Genomics
Jian Ding
Academician of CAE
SIMM
Baorui Liu
Director
Medical School of NJU
| Time | Theme | Speaker |
| 08:30-08:50 |
Registration and Coffee Refreshments |
|
| 08:50-09:00 |
Welcome Address: Chairman |
|
| 【Regulatory and Market of Asia CDx】 | ||
| 09:00-09:30 |
Regulatory Innovation for Companion Diagnostics in Asia, Market Development Status |
CFDA
|
| 09:30-10:00 |
New Regulatory Strategies for CDx Co-Development from PDMA’s View
|
Dr. Reiko Yanagihara,
Director of IVD Office,
PMDA
|
| 10:00-10:30 |
New Technologies Accelerating CDx Development in New Drug Discovery and Clinical Deployment |
Guoqing Cao,
Previous Vice President of Translational Medicine,
Hengrui Pharma
|
| 10:30-11:00 |
Biomarker and CDx--- The first half of Precision Medicine |
|
| 11:00-11:20: | Coffee Break And Networking | |
| 11:20-11:40 |
Rx-Dx Co-development Strategy: How to Choose the best Companion Partner in Drug Development
|
|
| 11:40-12:00 |
Commercialization Road of CDx |
Dr. Minzhi Ye，
Director of R&D Center
BGI
|
| 12:00-12:40 | Panel Discussion：Pharmaceutical (Rx) - Diagnostic (Dx) Co-development Strategy : How to deal with unknown regulatory risks?？ |
|
| 12:40-14:00 | Buffet Lunch | |
| 【From Biomarkers to Commercialization of CDx】 | ||
| 14:00-14:20 |
Next Generation Biomarkers Selection: Enriching CDx deployment in Clincal Trial |
|
| 14:20-14:40 |
Functional Diagnostics and Co-clinical Trial in CDx Development |
Dr. Danyi Wen,
President
Lide Biotech
|
| 14:40-15:10 |
Multiplex Crystal Digital™ PCR : Quantifying EGFR mutations from Single Cell Analysis with the Naica System |
Dr. Remi Dangla,
CEO,
Stilla Technologies
|
| 15:10-15:30 |
Providing Pharmaceutical Innovation with CDx Development and Clinical Testing Solutions |
Dr. Yizhe Zhang,
CEO
Shuwen Biotech
|
| 15:30-15:50 | Coffee Break And Networking | |
| 15:50-16:20 |
How to balance the investment of Biomarkers in New Drug Discovery : Evaluation of Biomarker Performance in the Real World |
|
| 16:20-16:50 |
Under the Venture Capital, Liquid Biopsy in the clinical Utility and Commercial Value |
|
| 16:50-17:30 | Novel Biomarker Selection in Pre-Clinical and Commercial Challenge? |
|
| End of DAY ONE | ||
| Time | Theme | Speaker |
| 08:30-08:50 |
Registration and Coffee Refreshments |
|
| 08:50-09:00 |
Welcome Address: Chairman |
|
| 【Novel Technology: Biomarker/NGS】 | ||
| 09:00-09:30 |
Discovery of Novel Biomarkers for the Development of Personalized Medicine |
|
| 09:30-10:00 |
Cancer Biomarker: From Discovery to Commercialization
|
Dr. Yang Qiu,
JNJ China R&D Center
Biomarker Lead
|
| 10:00-10:30 |
Adaptive Design Strategies for Maximizing the Efficiency of Clinical Oncology Development Programs with Predictive Biomarkers |
Dr. Jerry Wang,
Merck Serono China
Head of Biostatistics & Statistical Programming
|
| 10:30-11:00 |
Next-Generation Sequencing for Cancer Biomarker Discovery |
|
| 11:00-11:20: | Coffee Break And Networking | |
| 11:20-11:40 |
Next-Generation Sequencing as a Clinical Test : Great Tools for the Biomarker Discovery and Development |
|
| 11:40-12:00 |
China Third-Generation DNA Sequencer: Integrated DNA and RNA sequencing of single cells |
Jiankui He,
South University of Science and Technology of China
|
| 12:00-12:40 | Panel Discussion：How Next Generation Sequencing is Transforming Biomarker Discovery and New Drug Discovery |
|
| 12:40-14:00 | Buffet Lunch | |
| 【Cancer Precision Medicine and Liquid Biopsy】 | ||
| 14:00-14:20 |
The Progress of Bioinformatics Analysis About Tumor Precision Medicine |
Dr. Han Liang，
CSO&Co-founder,
Precision Scientific
|
| 14:20-14:40 |
Personalized Medicine: Redefining Cancer and It’s Treatment |
|
| 14:40-15:10 |
Applications of ctDNA Methylation Liquid Biopsy in Early Cancer Screening and Adjunctive Diagnositics |
Dr. Abraham KC Ho,
VP&Chief Medical Officer，
LAM Group
|
| 15:10-15:30 |
Advancing the Application of Next Generation Sequencing for Companion Diagnostics in Oncology |
|
| 15:30-15:50 | Coffee Break And Networking | |
| 15:50-16:20 |
ct-DNA,CTC Application in Cancer Precision Medicine, Improving Personal Oncology Treatment |
Dr. Bob Wang，
Agena Bio
GM, Greater China
|
| 16:20-16:50 |
Next Generation Immunotherapy Innovation Technology for Tumor Personal Medicine |
Dr. Bao-Rui Liu,
Nanjing University
|
| 16:50-17:30 | Panel Discussion：The Future of Personalized Cancer Medicine: Novel Technologies Transforming Cancer Treatment |
|
| End of DAY TWO | ||
| Item | Company | Clinical&Research&Academy |
| Two Day Conference | $ 1499 USD/per | $ 599 USD/per |
| VIP Reception Dinner | $ 599 USD/per | / |
|
Early Bird Discount |
Saving $200(Deadline:：2018/1/30) | |
Invited Speakers
Media Partners
Press Release
Senior Executive
Coverage Online To Offline
Media Exposure
Sponsor&Presentation
Jerry Chang
Exhibition&Delegate
Willson Wang
Coordinator Manager
Betty Chen
